Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Vecchiarelli, S. [1 ]
D'Incecco, A. [2 ]
Minuti, G. [1 ]
Gallo, M. [3 ]
De Luca, A. [3 ]
Landi, L. [1 ]
Bennati, C. [1 ]
Spreafico, M. [4 ]
D'Arcangelo, M. [1 ]
Attilia, L. [1 ]
Mazza, V. [1 ]
Normanno, N. [3 ]
Cappuzzo, F. [1 ]
机构：
[1] Ausl Romagna, Oncohematol Dept, Ravenna, Italy
[2] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[3] Fdn Giovanni Pascale, Ircc, Inst Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy
[4] Ist Sci Romagnolo Studio & Cura Tumori Irst, Unit Biostat & Clin Trials, Ravenna, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Immunotherapy; PD-L1; Non-Small Cell Lung Cancer (NSCLC);
D O I：
10.1016/j.jtho.2017.09.1934
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PUB071
引用
收藏
页码：S2389 / S2389
页数：1
相关论文
共 50 条
  • [21] Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
    Liang, Jiaqi
    Li, Ming
    Sui, Qihai
    Hu, Zhengyang
    Bian, Yunyi
    Huang, Yiwei
    Zhan, Cheng
    Jiang, Wei
    Wang, Qun
    Tan, Lijie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1302 - +
  • [22] Programmed death ligand 1 (PD-L1) expression status as prognostic factor in early stage non-small cell lung cancer (NSCLC)
    D'Arcangelo, M.
    Puccetti, M.
    Bravaccini, S.
    D'Incecco, A.
    Ligorio, C.
    Terracciano, L.
    Damiani, S.
    Bennati, C.
    Minuti, G.
    Vecchiarelli, S.
    Landi, L.
    Incarbone, M.
    Milesi, M.
    Ravaioli, S.
    Tumedei, M. M.
    Rossi, E.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US
    Kessler, Joshua E.
    Park, Kwon N.
    Grizzle, Amy J.
    Hurwitz, Jason T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (01) : 55 - 61
  • [24] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2018, 31 : 753 - 754
  • [25] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    LABORATORY INVESTIGATION, 2018, 98 : 753 - 754
  • [26] Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Sequist, Lecia V.
    Shaw, Alice Tsang
    Azzoli, Christopher G.
    Piotrowska, Zofia
    Huynh, Tiffany
    Fulton, Linnea
    Schultz, Katherine
    Hata, Aaron N.
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer
    Sepesi, Boris
    Cuentas, Edwin Parra
    Canales, Jaime Rodriguez
    Behrens, Carmen
    Correa, Arlene M.
    Vaporciyan, Ara
    Weissferdt, Annikka
    Kalhor, Neda
    Moran, Cesar
    Swisher, Stephen
    Wistuba, Ignacio
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2017, 29 (03) : 408 - 415
  • [28] Programmed death-ligand 1 (PD-L1) expression and testing experience in a cohort of advanced non-small cell lung cancer (NSCLC) patients
    Decatris, M.
    Hayes, M.
    Reed, N.
    Bhalla, V.
    Thomas, J.
    Gaikwad, K.
    Birchall, K.
    Phillips, A.
    Ryan, P.
    Du Rand, I.
    Taniere, P.
    LUNG CANCER, 2018, 115 : S42 - S42
  • [29] Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
    Antonia, Scott
    Rizvi, Naiyer
    Brahmer, Julie
    Ou, Sai-Hong
    Khleif, Samir N.
    Hwu, Wen-Jen
    Gutierrez, Martin
    Schoffski, Patrick
    Hamid, Omid
    Weiss, Jared
    Lutzky, Jose
    Maio, Michele
    Nemunaitis, John
    Jaeger, Dirk
    Balmanoukian, Ani
    Rebelatto, Marlon C.
    Steele, Keith E.
    Jin, Xiaoping
    Robbins, Paul B.
    Blake-Haskins, John A.
    Segal, Neil H.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [30] Correlation Between Programmed Death-1 (PD-1) Expression in Tumor Infiltrating Lymphocytes and Programmed Death Ligand-1 (PD-L1) Expression in Non-Small Cell Lung Carcinoma
    Driver, Brandon
    Miller, Ross A.
    Deavers, Michael
    Tacha, David
    Bernicker, Eric
    Cagle, Philip T.
    LABORATORY INVESTIGATION, 2017, 97 : 475A - 475A
12345